Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
P/E ratio for Generation Bio Co. (GBIO)
P/E ratio as of 2023: -0.84
According to Generation Bio Co.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.84. At the end of 2022 the company had a P/E ratio of -1.73.
P/E ratio history for Generation Bio Co. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.84 |
| 2022 | -1.73 |
| 2021 | -3.48 |
| 2020 | -10.10 |
| 2019 | -18.91 |
| 2018 | -13.58 |